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atinine of >25% from baseline during this 96 hour period. The trial was powered to detect 
a reduction in the primary endpoint from 30% to 15%. Secondary endpoints included 
hospital length of stay, adverse cardiac events, re-hospitalization and need for dialysis 
within 30 days. 
Results. In the pooled population, mean age was 70 + 11 years, 34% were female, 51% 
had diabetes, 67% hypertension, 50% prior MI, and 48% prior CHF. The baseline CrCl 
was 29.2 + 10.1 cc/min (range 7.5-57.5). Mean contrast dose was 164 ?; 155 cc. The 
mean hospital length of stay was 4.0 -+ 5.9 days. Within 30 days, 2.3% required dialysis, 
19.2% were re-hospitalized, and 3.2% of pts died. CIN within 24-96 hours of drug, the pri- 
mary endpoint, occurred in 30.5% of pts. 
Conclusfons. Desvite hvdration and contemoorarv catheterization techniaues. CIN is _ . 
common after invasive cardiac procedures in a population with baseline renal insuff- 
ciencv and oortends a ooor oroonosis. The results of CONTRAST. which examined the 
I  . _  
utility of fenoldopam mesylate. a specific Dl agonist, for the prevention of CIN will be 
unblinded for the first time for presentation in March 2003. 
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Intervention 
Fen Wei Wang, Abdulfatah Osman, Javier Otero, George A. Stouffer, Sergio Waxman, 
Adnan Afzal, Angelo Anzuini, BarN F. Uretsky, The University of Texas Medical Branch, 
Galveston, TX 
Background: Experimental studies have shown that IV beta blockers given before coro- 
nary artery occlusion significantly reduce myocardial injury. We tested the hypothesis 
that intracoronary (C) propranolol(O.015 mgikg) pre-coronary intervention (PCI) reduces 
myocardial necrosis (Ml) and short-term adverse outcomes after PCI. Methods Patients 
(n=150) undergoing elective or urgent PCI were randomly assigned in a prospective dou- 
ble-blind fashion to receive either IC propranolol (n=75) or placebo (n=75). Results 
Major adverse events through the first 30 days are shown in the table and figure. Con- 
clusion: lntracoronary administration of propranolol significantly reduces the incidence 
of Ml after PCI, improves short-term clinical outcomes, and suggests its routine use dur- 
ing PCI. 
30 day Results (% of patients) 
Propranolol (n=75) Placebo (n=75) P value 
Elevated CK-MB 17 36 0.01 
Elevated Troponin T 13 33 0.005 
Death 0 0 NS 
Recurrent Ml 1 3 NS 
Urgent TLR 0 3 NS 
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periprocedural myocardial infarction (MI, 5.7% vs 6.1% P=O.O36). At 1 year, statin pre- 
treatment was predictive of survival almost exclusively among patients within the highest 
CRP quartfle (CRP >l.ll mg/dL) (Figure). In multivariate analysis, the interaction 
between CRP quartiles and statin use remained significant (P=O.O14). After adjusting for 
the propensity of receiving statin, statin pretreatment was an independent predictor for l- 
year survival within the highest CRP quartile (H&0.44, P=O.O39). 
Conclusions: Statin therapy prior to PCI is associated with a marked survival benefit 
among patients with high CRP levels, suggesting mechanism tied to a particular anti- 
inflammatory effect. 
11:45 a.m. 
88OFO-6 Prophylactic Acetylcysteine Is Not Effective in 
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Background: Contrast-Induced Nephropathy (CIN) is associated with significant morbid- 
ity and mortality following coronary angiography. Oral acetylcysteine at a dose of 600 mg 
every twelve hours has had inconsistent results in preventing CIN following contrast 
administration in previously published reports. 
Methods: 96 patients with a creatinine clearance of 50 mllmin or less were randomized 
in a double blinded manner the evening prior to coronary angiography to receive four 
doses of acetylcysteine 1500 mg every twelve hours versus placebo. All patients 
received t/2 normal saline at 1 mlIkg for 12 hours before and 12 hours after angiography. 
CIN was defined as an increase from the baseline serum creatinine (SC) at 46 hours by 
25% or 0.5 mgldl. Multivariate analysis was utilized to identify the incidence of CIN as 
well as the absolute change in SC at 48 hours. 
Results: Baseline characteristics in the groups were similar, with a mean baseline SC of 
1.64 mg/dl. CIN developed in 4 of 49 (6.2%) patients in the acetylcysteine group and 3 of 
47 (6.4%) in the placebo group (p=O.74). Volume of contrast was similar between the two 
groups: 134 ml in the acetylcysteine group and 127 ml in the placebo group (p=O.63). 
The mean change in the SC from baseline and at 46 hours following contrast exposure 
was -0.01 mgldl in the acetylcysteine group and -0.05 mgldl in the placebo group 
(p=O.52). Multiple variables were analyzed with regards to mean change in SC at 48 
hours. The only significant covariate was the volume of contrast dye delivered (p=O.O3). 
There was no benefit of acetylcysteine on change in SC at 46 hours regardless of the 
severity of renal insufficiency. Acetylcysteine was tolerated as well as placebo. 
Conclusion: Acetylcysteine does not appear to prevent CIN in patients with a creatinine 
clearance less than 50 mg/dl who are undergoing coronary angiography. The volume of 
dye delivered continues to be recognized as a potent factor in the deterioration of kidney 
function following angiography. 
Background: Beyond lipid-lowering, statins possess anti-inflammatory and anti-throm- 
botic effects. The relation between statin therapy and lowering of death/Ml early after 
percutaneous coronary intervention (PCI) has been recently shown. We examined the 
inter-relationship of inflammation, statin use. and PCI outcome. 
Methods: Within the year 2000, 1,552 consecutive patients underwent elective/urgent 
PCI at the Cleveland Clinic and were prospectively followed. Pre-procedural serum high- 
sensitivity C-reactive protein (CRP) levels were measured. Comparisons were made 
between patients with and without statin pretreatment. 
Results: Statin-users (39.6%) had a lower median CRP level (0.40 mg/dl vs 0.50 mg/dl, 
P=O.O12) independent of the baseline cholesterol levels, and had less incidence of 
